Leo Innovation Lab says sale of spinoff is "stamp of approval"
The sale of healthcare app company Omhu to US-based Medable is the first time that Leo Innovation Lab has completely let go of one of its companies. CEO Anne Cathrine Fleischer sees the sale as a stamp of approval.
by ANDREAS LØNSTRUP, translated by catherine brett & daniel pedersen
Just two years after app company Omhu was spun out from Leo Innovation Lab, Leo has chosen to sell all of its shares in the firm to US-based Medable for an undisclosed sum. It is the first time that Leo Innovation Lab has sold the entirety of one of its spinoff companies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma sells app firm
For subscribers
Leo Pharma poaches Orphazyme CEO
For subscribers
Layoffs and restructuring will prepare Leo Pharma for IPO
For subscribers
